Development of immune checkpoint therapy for cancer

Jill M Fritz, Michael J Lenardo, Jill M Fritz, Michael J Lenardo

Abstract

Since the early 20th century, immunologists have investigated mechanisms that protect vertebrates from damaging immune responses against self-antigens by mature lymphocytes, i.e., peripheral tolerance. These mechanisms have been increasingly delineated at the molecular level, ultimately culminating in new therapeutics that have revolutionized clinical oncology. Here, we describe basic science and clinical discoveries that converge mainly on two molecules, CTLA-4 and PD-1, that were recognized with the 2018 Nobel Prize in Physiology or Medicine awarded to James Allison and Tasuku Honjo. We discuss their investigations and those of many others in the field that contravene tolerance through checkpoint inhibition to boost immune killing of malignant cells. We also discuss the mechanisms underlying each therapy, the efficacy achieved, and the complications of therapy. Finally, we hint at research questions for the future that could widen the success of cancer immunotherapy.

This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.

Figures

Figure 1.
Figure 1.
Mechanisms of CTLA-4 function and inhibition. (A–C) CTLA-4 is up-regulated on activated T cells and inhibits further T cell activation by competing with CD28 for B7 ligation. T reg cells, which constitutively express CTLA-4, trans-endocytose B7 ligands on APCs to prevent CD28 costimulation. (D) Blocking CTLA-4 results in enhanced CD28-B7 ligation, which unleashes T cell expansion and effector function. By inhibiting CTLA-4 on T reg cells, B7 trans-endocytosis is suppressed, resulting in increased APC potency. CTLA-4 blockade is also thought to cause T reg cell depletion through ADCC by cells expressing Fcγ receptors.
Figure 2.
Figure 2.
Mechanisms of PD-1 function and inhibition. (A and B) PD-1 is expressed by activated T cells and binds to PD-L1 and PD-L2 on APCs or other nonimmune cells to inhibit T cell signaling through a poorly defined mechanism. Chronic T cell signaling results in exhaustion and an inability to properly function. (C) PD-1/PD-L1 inhibition unleashes the expansion of CD4+ and CD8+ T cell populations, resulting in increased memory formation and cytotoxic T cell responses.

References

    1. Agata Y., Kawasaki A., Nishimura H., Ishida Y., Tsubata T., Yagita H., and Honjo T.. 1996. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8:765–772. 10.1093/intimm/8.5.765
    1. Arce Vargas F., Furness A.J.S., Litchfield K., Joshi K., Rosenthal R., Ghorani E., Solomon I., Lesko M.H., Ruef N., Roddie C., et al. TRACERx Melanoma. TRACERx Renal. TRACERx Lung consortia . 2018. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell. 33:649–663.e4.
    1. Bachmann M.F., Köhler G., Ecabert B., Mak T.W., and Kopf M.. 1999. Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J. Immunol. 163:1128–1131.
    1. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., et al. . 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366:2455–2465. 10.1056/NEJMoa1200694
    1. Bruhns P., Iannascoli B., England P., Mancardi D.A., Fernandez N., Jorieux S., and Daëron M.. 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 113:3716–3725. 10.1182/blood-2008-09-179754
    1. Calvo C.R., Amsen D., and Kruisbeek A.M.. 1997. Cytotoxic T lymphocyte antigen 4 (CTLA-4) interferes with extracellular signal-regulated kinase (ERK) and Jun NH2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor zeta and ZAP70. J. Exp. Med. 186:1645–1653. 10.1084/jem.186.10.1645
    1. Carthon B.C., Wolchok J.D., Yuan J., Kamat A., Ng Tang D.S., Sun J., Ku G., Troncoso P., Logothetis C.J., Allison J.P., and Sharma P.. 2010. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16:2861–2871. 10.1158/1078-0432.CCR-10-0569
    1. Chaput N., Lepage P., Coutzac C., Soularue E., Le Roux K., Monot C., Boselli L., Routier E., Cassard L., Collins M., et al. . 2017. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 28:1368–1379. 10.1093/annonc/mdx108
    1. Chen H., Liakou C.I., Kamat A., Pettaway C., Ward J.F., Tang D.N., Sun J., Jungbluth A.A., Troncoso P., Logothetis C., and Sharma P.. 2009. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc. Natl. Acad. Sci. USA. 106:2729–2734. 10.1073/pnas.0813175106
    1. Chuang E., Fisher T.S., Morgan R.W., Robbins M.D., Duerr J.M., Vander Heiden M.G., Gardner J.P., Hambor J.E., Neveu M.J., and Thompson C.B.. 2000. The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. Immunity. 13:313–322. 10.1016/S1074-7613(00)00031-5
    1. Collins A.V., Brodie D.W., Gilbert R.J., Iaboni A., Manso-Sancho R., Walse B., Stuart D.I., van der Merwe P.A., and Davis S.J.. 2002. The interaction properties of costimulatory molecules revisited. Immunity. 17:201–210. 10.1016/S1074-7613(02)00362-X
    1. Cooper M.D., Raymond D.A., Peterson R.D., South M.A., and Good R.A.. 1966. The functions of the thymus system and the bursa system in the chicken. J. Exp. Med. 123:75–102. 10.1084/jem.123.1.75
    1. Darlington P.J., Baroja M.L., Chau T.A., Siu E., Ling V., Carreno B.M., and Madrenas J.. 2002. Surface cytotoxic T lymphocyte-associated antigen 4 partitions within lipid rafts and relocates to the immunological synapse under conditions of inhibition of T cell activation. J. Exp. Med. 195:1337–1347. 10.1084/jem.20011868
    1. Dong H., Zhu G., Tamada K., and Chen L.. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5:1365–1369. 10.1038/70932
    1. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K., et al. . 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:793–800. 10.1038/nm730
    1. Dovedi S.J., Adlard A.L., Lipowska-Bhalla G., McKenna C., Jones S., Cheadle E.J., Stratford I.J., Poon E., Morrow M., Stewart R., et al. . 2014. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74:5458–5468. 10.1158/0008-5472.CAN-14-1258
    1. Eroglu Z., Kim D.W., Wang X., Camacho L.H., Chmielowski B., Seja E., Villanueva A., Ruchalski K., Glaspy J.A., Kim K.B., et al. . 2015. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur. J. Cancer. 51:2689–2697. 10.1016/j.ejca.2015.08.012
    1. Esfahani K., and Miller W.H. Jr. 2017. Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade. N. Engl. J. Med. 376:1989–1991. 10.1056/NEJMc1703047
    1. Facciabene A., Motz G.T., and Coukos G.. 2012. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 72:2162–2171. 10.1158/0008-5472.CAN-11-3687
    1. Fehlings M., Simoni Y., Penny H.L., Becht E., Loh C.Y., Gubin M.M., Ward J.P., Wong S.C., Schreiber R.D., and Newell E.W.. 2017. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells. Nat. Commun. 8:562 10.1038/s41467-017-00627-z
    1. Fife B.T., Pauken K.E., Eagar T.N., Obu T., Wu J., Tang Q., Azuma M., Krummel M.F., and Bluestone J.A.. 2009. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol. 10:1185–1192. 10.1038/ni.1790
    1. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., et al. . 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192:1027–1034. 10.1084/jem.192.7.1027
    1. Furness A.J., Vargas F.A., Peggs K.S., and Quezada S.A.. 2014. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol. 35:290–298. 10.1016/j.it.2014.05.002
    1. Golden E.B., Demaria S., Schiff P.B., Chachoua A., and Formenti S.C.. 2013. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res. 1:365–372. 10.1158/2326-6066.CIR-13-0115
    1. Grulich A.E., van Leeuwen M.T., Falster M.O., and Vajdic C.M.. 2007. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 370:59–67. 10.1016/S0140-6736(07)61050-2
    1. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., et al. . 2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369:134–144. 10.1056/NEJMoa1305133
    1. Harbour S.N., Maynard C.L., Zindl C.L., Schoeb T.R., and Weaver C.T.. 2015. Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis. Proc. Natl. Acad. Sci. USA. 112:7061–7066. 10.1073/pnas.1415675112
    1. He M., Chai Y., Qi J., Zhang C.W.H., Tong Z., Shi Y., Yan J., Tan S., and Gao G.F.. 2017. Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. Oncotarget. 8:67129–67139.
    1. Herbst R.S., Soria J.C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., Sosman J.A., McDermott D.F., Powderly J.D., Gettinger S.N., et al. . 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515:563–567. 10.1038/nature14011
    1. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., Davis T., Henry-Spires R., MacRae S., Willman A., et al. . 2003. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA. 100:4712–4717. 10.1073/pnas.0830997100
    1. Hodi F.S., O’Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. . 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711–723. 10.1056/NEJMoa1003466
    1. Hoos A., Ibrahim R., Korman A., Abdallah K., Berman D., Shahabi V., Chin K., Canetta R., and Humphrey R.. 2010. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin. Oncol. 37:533–546. 10.1053/j.seminoncol.2010.09.015
    1. Horvat T.Z., Adel N.G., Dang T.O., Momtaz P., Postow M.A., Callahan M.K., Carvajal R.D., Dickson M.A., D’Angelo S.P., Woo K.M., et al. . 2015. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J. Clin. Oncol. 33:3193–3198. 10.1200/JCO.2015.60.8448
    1. Hou T.Z., Qureshi O.S., Wang C.J., Baker J., Young S.P., Walker L.S., and Sansom D.M.. 2015. A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells. J. Immunol. 194:2148–2159. 10.4049/jimmunol.1401876
    1. Iijima N., and Iwasaki A.. 2016. Access of protective antiviral antibody to neuronal tissues requires CD4 T-cell help. Nature. 533:552–556. 10.1038/nature17979
    1. Im S.J., Hashimoto M., Gerner M.Y., Lee J., Kissick H.T., Burger M.C., Shan Q., Hale J.S., Lee J., Nasti T.H., et al. . 2016. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 537:417–421. 10.1038/nature19330
    1. Ishida Y., Agata Y., Shibahara K., and Honjo T.. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895. 10.1002/j.1460-2075.1992.tb05481.x
    1. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., and Minato N.. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA. 99:12293–12297. 10.1073/pnas.192461099
    1. Iwai Y., Terawaki S., and Honjo T.. 2005. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17:133–144. 10.1093/intimm/dxh194
    1. Juneja V.R., McGuire K.A., Manguso R.T., LaFleur M.W., Collins N., Haining W.N., Freeman G.J., and Sharpe A.H.. 2017. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J. Exp. Med. 214:895–904. 10.1084/jem.20160801
    1. Kavanagh B., O’Brien S., Lee D., Hou Y., Weinberg V., Rini B., Allison J.P., Small E.J., and Fong L.. 2008. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 112:1175–1183. 10.1182/blood-2007-11-125435
    1. Kim H.J., Verbinnen B., Tang X., Lu L., and Cantor H.. 2010. Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance. Nature. 467:328–332. 10.1038/nature09370
    1. Kong K.F., Fu G., Zhang Y., Yokosuka T., Casas J., Canonigo-Balancio A.J., Becart S., Kim G., Yates J.R. III, Kronenberg M., et al. . 2014. Protein kinase C-η controls CTLA-4-mediated regulatory T cell function. Nat. Immunol. 15:465–472. 10.1038/ni.2866
    1. Krummel M.F., and Allison J.P.. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183:2533–2540. 10.1084/jem.183.6.2533
    1. Kuang D.M., Zhao Q., Peng C., Xu J., Zhang J.P., Wu C., and Zheng L.. 2009. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206:1327–1337. 10.1084/jem.20082173
    1. Kuehn H.S., Ouyang W., Lo B., Deenick E.K., Niemela J.E., Avery D.T., Schickel J.N., Tran D.Q., Stoddard J., Zhang Y., et al. . 2014. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 345:1623–1627. 10.1126/science.1255904
    1. Kwon E.D., Hurwitz A.A., Foster B.A., Madias C., Feldhaus A.L., Greenberg N.M., Burg M.B., and Allison J.P.. 1997. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA. 94:8099–8103. 10.1073/pnas.94.15.8099
    1. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., Schadendorf D., Dummer R., Smylie M., Rutkowski P., et al. . 2015. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 373:23–34. 10.1056/NEJMoa1504030
    1. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., Iwai Y., Long A.J., Brown J.A., Nunes R., et al. . 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2:261–268. 10.1038/85330
    1. Leach D.R., Krummel M.F., and Allison J.P.. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 271:1734–1736. 10.1126/science.271.5256.1734
    1. Lee K.M., Chuang E., Griffin M., Khattri R., Hong D.K., Zhang W., Straus D., Samelson L.E., Thompson C.B., and Bluestone J.A.. 1998. Molecular basis of T cell inactivation by CTLA-4. Science. 282:2263–2266. 10.1126/science.282.5397.2263
    1. Lee S., Moon J.S., Lee C.R., Kim H.E., Baek S.M., Hwang S., Kang G.H., Seo J.K., Shin C.H., Kang H.J., et al. . 2016. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J. Allergy Clin. Immunol. 137:327–330. 10.1016/j.jaci.2015.08.036
    1. Lenardo M., Chan K.M., Hornung F., McFarland H., Siegel R., Wang J., and Zheng L.. 1999. Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 17:221–253. 10.1146/annurev.immunol.17.1.221
    1. Liakou C.I., Kamat A., Tang D.N., Chen H., Sun J., Troncoso P., Logothetis C., and Sharma P.. 2008. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl. Acad. Sci. USA. 105:14987–14992. 10.1073/pnas.0806075105
    1. Lo B., Zhang K., Lu W., Zheng L., Zhang Q., Kanellopoulou C., Zhang Y., Liu Z., Fritz J.M., Marsh R., et al. . 2015. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 349:436–440. 10.1126/science.aaa1663
    1. Maker A.V., Attia P., and Rosenberg S.A.. 2005. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175:7746–7754. 10.4049/jimmunol.175.11.7746
    1. Mandelbrot D.A., McAdam A.J., and Sharpe A.H.. 1999. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J. Exp. Med. 189:435–440. 10.1084/jem.189.2.435
    1. Masopust D., Vezys V., Wherry E.J., and Ahmed R.. 2007. A brief history of CD8 T cells. Eur. J. Immunol. 37(Suppl 1):S103–S110. 10.1002/eji.200737584
    1. McGranahan N., Furness A.J., Rosenthal R., Ramskov S., Lyngaa R., Saini S.K., Jamal-Hanjani M., Wilson G.A., Birkbak N.J., Hiley C.T., et al. . 2016. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 351:1463–1469. 10.1126/science.aaf1490
    1. Miller J.F. 1961. Immunological function of the thymus. Lancet. 2:748–749. 10.1016/S0140-6736(61)90693-6
    1. Miller J.F., and Mitchell G.F.. 1967. The thymus and the precursors of antigen reactive cells. Nature. 216:659–663. 10.1038/216659a0
    1. Miller J.F., and Morahan G.. 1992. Peripheral T cell tolerance. Annu. Rev. Immunol. 10:51–69. 10.1146/annurev.iy.10.040192.000411
    1. Misra N., Bayry J., Lacroix-Desmazes S., Kazatchkine M.D., and Kaveri S.V.. 2004. Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J. Immunol. 172:4676–4680. 10.4049/jimmunol.172.8.4676
    1. Nakanishi Y., Lu B., Gerard C., and Iwasaki A.. 2009. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature. 462:510–513. 10.1038/nature08511
    1. Ngwa W., Irabor O.C., Schoenfeld J.D., Hesser J., Demaria S., and Formenti S.C.. 2018. Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer. 18:313–322. 10.1038/nrc.2018.6
    1. Nishimura H., Nose M., Hiai H., Minato N., and Honjo T.. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 11:141–151. 10.1016/S1074-7613(00)80089-8
    1. Nishimura H., Okazaki T., Tanaka Y., Nakatani K., Hara M., Matsumori A., Sasayama S., Mizoguchi A., Hiai H., Minato N., and Honjo T.. 2001. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 291:319–322. 10.1126/science.291.5502.319
    1. O’Mahony D., Morris J.C., Quinn C., Gao W., Wilson W.H., Gause B., Pittaluga S., Neelapu S., Brown M., Fleisher T.A., et al. . 2007. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin. Cancer Res. 13:958–964. 10.1158/1078-0432.CCR-06-1974
    1. Oderup C., Cederbom L., Makowska A., Cilio C.M., and Ivars F.. 2006. Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression. Immunology. 118:240–249. 10.1111/j.1365-2567.2006.02362.x
    1. Okazaki T., and Honjo T.. 2007. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19:813–824. 10.1093/intimm/dxm057
    1. Okazaki T., Maeda A., Nishimura H., Kurosaki T., and Honjo T.. 2001. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. USA. 98:13866–13871. 10.1073/pnas.231486598
    1. Okazaki T., Iwai Y., and Honjo T.. 2002. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr. Opin. Immunol. 14:779–782. 10.1016/S0952-7915(02)00398-9
    1. Patsoukis N., Bardhan K., Chatterjee P., Sari D., Liu B., Bell L.N., Karoly E.D., Freeman G.J., Petkova V., Seth P., et al. . 2015. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun. 6:6692 10.1038/ncomms7692
    1. Pauken K.E., and Wherry E.J.. 2015. SnapShot: T Cell Exhaustion. Cell. 163:1038–1038.e1.
    1. Peggs K.S., Quezada S.A., Chambers C.A., Korman A.J., and Allison J.P.. 2009. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206:1717–1725. 10.1084/jem.20082492
    1. Penaloza-MacMaster P., Kamphorst A.O., Wieland A., Araki K., Iyer S.S., West E.E., O’Mara L., Yang S., Konieczny B.T., Sharpe A.H., et al. . 2014. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J. Exp. Med. 211:1905–1918. 10.1084/jem.20132577
    1. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., Restifo N.P., Haworth L.R., Seipp C.A., Freezer L.J., et al. . 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA. 100:8372–8377. 10.1073/pnas.1533209100
    1. Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., Mu Z., Rasalan T., Adamow M., Ritter E., et al. . 2012. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366:925–931. 10.1056/NEJMoa1112824
    1. Postow M.A., Chesney J., Pavlick A.C., Robert C., Grossmann K., McDermott D., Linette G.P., Meyer N., Giguere J.K., Agarwala S.S., et al. . 2015. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372:2006–2017. 10.1056/NEJMoa1414428
    1. Postow M.A., Sidlow R., and Hellmann M.D.. 2018. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N. Engl. J. Med. 378:158–168. 10.1056/NEJMra1703481
    1. Powles T., Eder J.P., Fine G.D., Braiteh F.S., Loriot Y., Cruz C., Bellmunt J., Burris H.A., Petrylak D.P., Teng S.L., et al. . 2014. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 515:558–562. 10.1038/nature13904
    1. Quezada S.A., Peggs K.S., Curran M.A., and Allison J.P.. 2006. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116:1935–1945. 10.1172/JCI27745
    1. Quigley M.F., Gonzalez V.D., Granath A., Andersson J., and Sandberg J.K.. 2007. CXCR5+ CCR7- CD8 T cells are early effector memory cells that infiltrate tonsil B cell follicles. Eur. J. Immunol. 37:3352–3362. 10.1002/eji.200636746
    1. Qureshi O.S., Zheng Y., Nakamura K., Attridge K., Manzotti C., Schmidt E.M., Baker J., Jeffery L.E., Kaur S., Briggs Z., et al. . 2011. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 332:600–603. 10.1126/science.1202947
    1. Ramagopal U.A., Liu W., Garrett-Thomson S.C., Bonanno J.B., Yan Q., Srinivasan M., Wong S.C., Bell A., Mankikar S., Rangan V.S., et al. . 2017. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. Proc. Natl. Acad. Sci. USA. 114:E4223–E4232. 10.1073/pnas.1617941114
    1. Read S., Malmström V., and Powrie F.. 2000. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. 192:295–302. 10.1084/jem.192.2.295
    1. Ribas A., Camacho L.H., Lopez-Berestein G., Pavlov D., Bulanhagui C.A., Millham R., Comin-Anduix B., Reuben J.M., Seja E., Parker C.A., et al. . 2005. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol. 23:8968–8977. 10.1200/JCO.2005.01.109
    1. Ribas A., Kefford R., Marshall M.A., Punt C.J., Haanen J.B., Marmol M., Garbe C., Gogas H., Schachter J., Linette G., et al. . 2013. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31:616–622. 10.1200/JCO.2012.44.6112
    1. Ribas A., Shin D.S., Zaretsky J., Frederiksen J., Cornish A., Avramis E., Seja E., Kivork C., Siebert J., Kaplan-Lefko P., et al. . 2016. PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol. Res. 4:194–203. 10.1158/2326-6066.CIR-15-0210
    1. Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., Lee W., Yuan J., Wong P., Ho T.S., et al. . 2015. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 348:124–128. 10.1126/science.aaa1348
    1. Robert C., Thomas L., Bondarenko I., O’Day S., Weber J., Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J., et al. . 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364:2517–2526. 10.1056/NEJMoa1104621
    1. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., Weber J.S., Joshua A.M., Hwu W.J., Gangadhar T.C., et al. . 2014. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 384:1109–1117. 10.1016/S0140-6736(14)60958-2
    1. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., Hassel J.C., Rutkowski P., McNeil C., Kalinka-Warzocha E., et al. . 2015a Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372:320–330. 10.1056/NEJMoa1412082
    1. Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., Daud A., Carlino M.S., McNeil C., Lotem M., et al. KEYNOTE-006 investigators . 2015b Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 372:2521–2532. 10.1056/NEJMoa1503093
    1. Romano E., Kusio-Kobialka M., Foukas P.G., Baumgaertner P., Meyer C., Ballabeni P., Michielin O., Weide B., Romero P., and Speiser D.E.. 2015. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc. Natl. Acad. Sci. USA. 112:6140–6145. 10.1073/pnas.1417320112
    1. Rosenberg J.E., Hoffman-Censits J., Powles T., van der Heijden M.S., Balar A.V., Necchi A., Dawson N., O’Donnell P.H., Balmanoukian A., Loriot Y., et al. . 2016. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 387:1909–1920. 10.1016/S0140-6736(16)00561-4
    1. Rota G., Niogret C., Dang A.T., Barros C.R., Fonta N.P., Alfei F., Morgado L., Zehn D., Birchmeier W., Vivier E., and Guarda G.. 2018. Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo. Cell Reports. 23:39–49. 10.1016/j.celrep.2018.03.026
    1. Sahin U., and Türeci Ö.. 2018. Personalized vaccines for cancer immunotherapy. Science. 359:1355–1360. 10.1126/science.aar7112
    1. Sansom D.M. 2000. CD28, CTLA-4 and their ligands: who does what and to whom? Immunology. 101:169–177. 10.1046/j.1365-2567.2000.00121.x
    1. Schadendorf D., Hodi F.S., Robert C., Weber J.S., Margolin K., Hamid O., Patt D., Chen T.T., Berman D.M., and Wolchok J.D.. 2015. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J. Clin. Oncol. 33:1889–1894. 10.1200/JCO.2014.56.2736
    1. Schneider H., Mandelbrot D.A., Greenwald R.J., Ng F., Lechler R., Sharpe A.H., and Rudd C.E.. 2002. Cutting edge: CTLA-4 (CD152) differentially regulates mitogen-activated protein kinases (extracellular signal-regulated kinase and c-Jun N-terminal kinase) in CD4+ T cells from receptor/ligand-deficient mice. J. Immunol. 169:3475–3479. 10.4049/jimmunol.169.7.3475
    1. Schubert D., Bode C., Kenefeck R., Hou T.Z., Wing J.B., Kennedy A., Bulashevska A., Petersen B.S., Schäffer A.A., Grüning B.A., et al. . 2014. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat. Med. 20:1410–1416. 10.1038/nm.3746
    1. Selby M.J., Engelhardt J.J., Quigley M., Henning K.A., Chen T., Srinivasan M., and Korman A.J.. 2013. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1:32–42. 10.1158/2326-6066.CIR-13-0013
    1. Sheppard K.A., Fitz L.J., Lee J.M., Benander C., George J.A., Wooters J., Qiu Y., Jussif J.M., Carter L.L., Wood C.R., and Chaudhary D.. 2004. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 574:37–41. 10.1016/j.febslet.2004.07.083
    1. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., Bergerhoff K., Arce F., Roddie C., Henry J.Y., Yagita H., Wolchok J.D., et al. . 2013. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210:1695–1710. 10.1084/jem.20130579
    1. Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., Walsh L.A., Postow M.A., Wong P., Ho T.S., et al. . 2014. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371:2189–2199. 10.1056/NEJMoa1406498
    1. Strebhardt K., and Ullrich A.. 2008. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat. Rev. Cancer. 8:473–480. 10.1038/nrc2394
    1. Takahashi T., Tagami T., Yamazaki S., Uede T., Shimizu J., Sakaguchi N., Mak T.W., and Sakaguchi S.. 2000. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192:303–310. 10.1084/jem.192.2.303
    1. Takeuchi Y., Tanemura A., Tada Y., Katayama I., Kumanogoh A., and Nishikawa H.. 2018. Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. Int. Immunol. 30:13–22. 10.1093/intimm/dxx073
    1. Tarhini A.A., Edington H., Butterfield L.H., Lin Y., Shuai Y., Tawbi H., Sander C., Yin Y., Holtzman M., Johnson J., et al. . 2014. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 9:e87705 10.1371/journal.pone.0087705
    1. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., and Sharpe A.H.. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 3:541–547. 10.1016/1074-7613(95)90125-6
    1. Tivol E.A., Boyd S.D., McKeon S., Borriello F., Nickerson P., Strom T.B., and Sharpe A.H.. 1997. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J. Immunol. 158:5091–5094.
    1. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. . 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:2443–2454. 10.1056/NEJMoa1200690
    1. Tseng S.Y., Otsuji M., Gorski K., Huang X., Slansky J.E., Pai S.I., Shalabi A., Shin T., Pardoll D.M., and Tsuchiya H.. 2001. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193:839–846. 10.1084/jem.193.7.839
    1. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J., Robert L., Chmielowski B., Spasic M., Henry G., Ciobanu V., et al. . 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515:568–571. 10.1038/nature13954
    1. Twyman-Saint Victor C., Rech A.J., Maity A., Rengan R., Pauken K.E., Stelekati E., Benci J.L., Xu B., Dada H., Odorizzi P.M., et al. . 2015. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 520:373–377. 10.1038/nature14292
    1. Van Allen E.M., Miao D., Schilling B., Shukla S.A., Blank C., Zimmer L., Sucker A., Hillen U., Foppen M.H.G., Goldinger S.M., et al. . 2015. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 350:207–211. 10.1126/science.aad0095
    1. van der Merwe P.A., Bodian D.L., Daenke S., Linsley P., and Davis S.J.. 1997. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J. Exp. Med. 185:393–403. 10.1084/jem.185.3.393
    1. van der Windt G.J., Everts B., Chang C.H., Curtis J.D., Freitas T.C., Amiel E., Pearce E.J., and Pearce E.L.. 2012. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity. 36:68–78. 10.1016/j.immuni.2011.12.007
    1. van Rooij N., van Buuren M.M., Philips D., Velds A., Toebes M., Heemskerk B., van Dijk L.J., Behjati S., Hilkmann H., El Atmioui D., et al. . 2013. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31:e439–e442. 10.1200/JCO.2012.47.7521
    1. Walker L.S., and Sansom D.M.. 2011. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 11:852–863. 10.1038/nri3108
    1. Walunas T.L., Bakker C.Y., and Bluestone J.A.. 1996. CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J Exp Med. 1996;184:301]. J. Exp. Med. 183:2541–2550. 10.1084/jem.183.6.2541
    1. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., Thompson C.B., Griesser H., and Mak T.W.. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 270:985–988. 10.1126/science.270.5238.985
    1. Weber J.S., D’Angelo S.P., Minor D., Hodi F.S., Gutzmer R., Neyns B., Hoeller C., Khushalani N.I., Miller W.H. Jr., Lao C.D., et al. . 2015. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16:375–384. 10.1016/S1470-2045(15)70076-8
    1. Wei S.C., Levine J.H., Cogdill A.P., Zhao Y., Anang N.A.S., Andrews M.C., Sharma P., Wang J., Wargo J.A., Pe’er D., and Allison J.P.. 2017. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell. 170:1120–1133.e17.
    1. Wherry E.J., and Kurachi M.. 2015. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15:486–499. 10.1038/nri3862
    1. Williams M.A., and Bevan M.J.. 2007. Effector and memory CTL differentiation. Annu. Rev. Immunol. 25:171–192. 10.1146/annurev.immunol.25.022106.141548
    1. Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., Nomura T., and Sakaguchi S.. 2008. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 322:271–275. 10.1126/science.1160062
    1. Yanai S., Nakamura S., and Matsumoto T.. 2017. Nivolumab-Induced Colitis Treated by Infliximab. Clin. Gastroenterol. Hepatol. 15:e80–e81. 10.1016/j.cgh.2016.09.017
    1. Yokosuka T., Kobayashi W., Takamatsu M., Sakata-Sogawa K., Zeng H., Hashimoto-Tane A., Yagita H., Tokunaga M., and Saito T.. 2010. Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity. 33:326–339. 10.1016/j.immuni.2010.09.006
    1. Zaugg K., Yao Y., Reilly P.T., Kannan K., Kiarash R., Mason J., Huang P., Sawyer S.K., Fuerth B., Faubert B., et al. . 2011. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 25:1041–1051. 10.1101/gad.1987211
    1. Zhang L., Gajewski T.F., and Kline J.. 2009. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 114:1545–1552. 10.1182/blood-2009-03-206672

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever